KDR and Hypertension: Abdel-Qadir et al. [58] conducted a comprehensive meta-analysis that quantified the cardiovascular toxicity of VEGFR inhibitions in the treatment of patients with malignancy including the increased risk of hypertension (odds ratio, OR 5.28), cardiac ischemia (OR 2.83), cardiac dysfunction (OR 1.35), and arterial thromboembolism (OR 1.52).